A084990 Stock Overview
Helixmith Co., Ltd develops biologic and natural nutraceutical products.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Helixmith Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,260.00 |
| 52 Week High | ₩9,720.00 |
| 52 Week Low | ₩3,250.00 |
| Beta | 1.12 |
| 1 Month Change | 2.16% |
| 3 Month Change | 11.08% |
| 1 Year Change | -54.92% |
| 3 Year Change | -83.29% |
| 5 Year Change | -97.18% |
| Change since IPO | -71.29% |
Recent News & Updates
Shareholder Returns
| A084990 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -0.2% | 1.9% | -1.2% |
| 1Y | -54.9% | -1.9% | 3.0% |
Return vs Industry: A084990 underperformed the KR Biotechs industry which returned -1.9% over the past year.
Return vs Market: A084990 underperformed the KR Market which returned 3% over the past year.
Price Volatility
| A084990 volatility | |
|---|---|
| A084990 Average Weekly Movement | 14.3% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 12.0% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A084990's share price has been volatile over the past 3 months.
Volatility Over Time: A084990's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 61 | Ji-Wook Jeong | www.helixmith.com |
Helixmith Co., Ltd develops biologic and natural nutraceutical products. The company offers LAYLA Tab for osteoarthritis; Allex and Allex i for hypersensitivity improvement; and Mnemosyne for memory improvement. Its lead gene therapy product is Engensis (VM202), which is in a phase III clinical trial for diabetic peripheral neuropathy and diabetic foot ulcer; a phase II clinical trial for amyotrophic lateral sclerosis (ALS) and claudication; and a phase I clinical trial for charcot-marie-tooth disease and coronary artery disease.
Helixmith Co., Ltd Fundamentals Summary
| A084990 fundamental statistics | |
|---|---|
| Market cap | ₩208.82b |
| Earnings (TTM) | -₩64.09b |
| Revenue (TTM) | ₩4.20b |
49.7x
P/S Ratio-3.3x
P/E RatioIs A084990 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A084990 income statement (TTM) | |
|---|---|
| Revenue | ₩4.20b |
| Cost of Revenue | ₩2.10b |
| Gross Profit | ₩2.10b |
| Other Expenses | ₩66.19b |
| Earnings | -₩64.09b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.31k |
| Gross Margin | 50.01% |
| Net Profit Margin | -1,525.33% |
| Debt/Equity Ratio | 13.1% |
How did A084990 perform over the long term?
See historical performance and comparison